This information was published on 2026-03-10T13:41:26 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2626903 (IR 1901555) |
| (220) |
08 Jan 2026
|
| (300) |
US, 04 Aug 2025, 99319317
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment and prevention of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Class 35 Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals. Class 44 Consultancy in the field of the medical treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; consultancy in the field of the medical diagnosis of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; health care services, namely, providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; health care services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders. |
| (540) | DAYBUE STIX |
| (550) | Word |
| (730) |
ACADIA Pharmaceuticals Inc.
|
Find out more about publications on the About page.